Somatotropin
- Generic Name
- Somatotropin
- Brand Names
- Genotropin, Humatrope, Norditropin, Norditropin Nordiflex, Nutropin, Nutropinaq, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, NutropinAq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12629-01-5
- Unique Ingredient Identifier
- NQX9KB6PCL
- Background
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland. Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and li...
- Indication
Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and shor...
- Associated Conditions
- Adult Onset Growth Hormone Deficiency, Cachexia, Childhood-onset Growth Hormone Deficiency, Growth Failure, HIV Wasting Syndrome, Short Bowel Syndrome (SBS), Short Stature
- Associated Therapies
- -
Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency
- Conditions
- First Posted Date
- 2000-10-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 72
- Registration Number
- NCT00006394
- Locations
- 🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 1
- Registration Number
- NCT00004815
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 109
- Registration Number
- NCT00004340
- Locations
- 🇺🇸
University of California Los Angeles School of Medicine, Los Angeles, California, United States
Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2008-09-10
- Target Recruit Count
- 80
- Registration Number
- NCT00004275
- Locations
- 🇺🇸
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 25
- Registration Number
- NCT00004429
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.